Vitiligo is a depigmenting disorder of the skin that is characterized by the loss of functional melanocytes from the lesional sites. Although the exact etiology is not understood, autoimmunity is thought to be a crucial deterministic factor. A recurring theme of several autoimmune disorders is the aberrant presentation of selfantigens to the immune system, which triggers downstream perturbations. Here we examine the role of alleles of HLA class I and class II loci to delineate vitiligo manifestation in two distinct populations. Our studies have identified three specific alleles, HLA-A*33:01, HLA-B*44:03, and HLA-DRB1*07:01, to be significantly increased in vitiligo patients as compared with controls in both the initial study on North Indians (N ¼ 1,404) and the replication study in Gujarat (N ¼ 355) cases, establishing their positive association with vitiligo. Both generalized and localized vitiligo have the same predisposing major histocompatibility complex alleles, i.e., B*44:03 and DRB1*07:01, in both the populations studied, beside the differences in the frequencies of other alleles, suggesting that localized vitiligo too may be an autoimmune disorder. Significant differences in the amino-acid signatures of the peptide-binding pockets of HLA-A and HLA-B a-chain and HLA-DR b-chain were observed between vitiligo patients and unaffected controls.
INTRODUCTION
Vitiligo is a multifactorial, depigmenting disorder of the skin characterized by loss of functional melanocytes, resulting in appearance of milky white patches on the skin. It is the most common pigmentation disorder affecting 0.5-1% of the world population (Taieb and Picardo, 2007) . In India, the incidence varies from 0.25 to 2.5% (Das et al., 1985; Handa and Kaur, 1999) in most ethnic groups, with 8.8% in populations from western states of Gujarat and Rajasthan (Shajil et al., 2006) . Vitiligo manifests in broadly two clinical subtypes: generalized and localized (Taieb and Picardo, 2007) . Generalized vitiligo includes vitiligo vulgaris, acrofacial vitiligo, and vitiligo universalis. Localized vitiligo includes segmental and focal types (Taieb and Picardo, 2007) . Precise etiology of vitiligo is not known; however, several hypotheses have been proposed, which include autoimmune (Kemp et al., 2001) , neural (Dell'anna and Picardo, 2006) , autocytotoxic (Lerner, 1971) , and genetic hypotheses (Bhatia et al., 1992) . Of these, autoimmune hypothesis remains most widely accepted because of frequent occurrence of other autoimmune diseases in vitiligo cases, the presence of autoreactive T cells in the vitiligenous lesions and peripheral circulation, and the presence of circulating autoantibodies in the sera of the patients (Schwartz and Janniger, 1997; Kovacs, 1998; Kemp et al., 2001; Lang et al., 2001; Wankowicz-Kalinska et al., 2003; van den Boorn et al., 2009; Waterman et al., 2010) . The frequency of vitiligo cases in first-degree relatives is B7%, suggesting an important role of genetic factors in disease pathogenesis (Majumder et al., 1993; Alkhateeb et al., 2003) .
The major histocompatibility complex (MHC) has been implicated in recent genome-wide association studies on vitiligo (Jin et al., 2010; Quan et al., 2010) , in which several single-nucleotide polymorphisms in the MHC region were significantly associated with the disease. However, the authors imputed the HLA (MHC of man) class I alleles, based on the linkage disequilibrium (LD) of HLA alleles with the specific single-nucleotide polymorphisms, but could not impute HLA class II alleles because of limitations of HLA allele imputation in the Chinese Han from Beijing (China) samples (Quan et al., 2010) . MHC spans about 3.6 megabases on chromosome 6p21.3 of man (Horton et al., 2004) , with 224 known gene loci. HLA is the most polymorphic system of the human genome, with 1,519 alleles for HLA-A locus, 2,069 alleles of HLA-B locus, 1,016 alleles for HLA-C locus, and 966 alleles for HLA-DRB1. With such a great diversity at each locus, LD of HLA alleles with diallelic single-nucleotide polymorphisms may be misleading, as several HLA alleles may be in LD with one or the alternate single-nucleotide polymorphism. Thus, the derivation based on these LDs may not be accurate, especially in the populations from which no previous HLA data are available. Thus, it is important to study the frequencies of HLA alleles in patients rather than imputing based on LD.
Many autoimmune diseases such as Type 1 diabetes (Todd et al., 1987; Rani et al., 2004) and rheumatoid arthritis (Winchester, 1994) have been shown to be associated with specific alleles of one or more genes of the MHC. The association of multiple HLA class I and class II antigens have been suggested for vitiligo (de Vijlder et al., 2004; Zhang et al., 2004a, b) , although no consensus could be reached, because of distinct ethnic groups (Zamani et al., 2001; Tastan et al., 2004; Orozco-Topete et al., 2005) , small sample sizes, and low-resolution typing methods used to identify the HLA antigens. We report here a very robust study on a sample size of 1,404 vitiligo cases and 902 unaffected controls from North India for the alleles at HLA-A, -B, and -C (class I), and -DRB1 (class II) loci using molecular methods. The replication study was conducted on 355 cases and 441 controls from Gujarat (Table 1) . We also report differences in the aminoacid signatures of peptide-binding pockets of the HLA molecules in vitiligo patients as compared with controls.
RESULTS

HLA class I and II alleles and haplotypes in vitiligo cases as compared with unaffected controls
Diversity in the number and frequencies of HLA alleles was observed both in patients and controls. We observed 78, 160, 35, and 106 alleles for HLA-A, -B, -C, and -DRB1 loci, respectively, in cases, and 68, 111, 44, and 94 alleles for HLA-A, -B, -C, and -DRB1 loci, respectively, in unaffected controls from North India, and similar diversity was observed in the replication study. However, HLA-A*33:01, B*44:03, C*07:01, DRB1*07:01, and DRB1*12:02 were significantly increased, and HLA-A*26:01, A*31:01, B*08:01, B*51:01, C*12:03, DRB1*03:01, DRB1*11:01, and DRB1*15:02 were significantly reduced (Table 2 and Supplementary Table S1 online) in the vitiligo subjects from North India as compared with controls. In the replication study, we observed HLA-A*33:01, B*44:03, and DRB1*07:01 to be significantly increased, and DRB1*03:01 and DRB1*11:01 to be significantly reduced in the cases as compared with ethnically matched controls (Table 2) . These associations were significant, irrespective of the age at onset or the gender of the cases ( Supplementary Tables S2-S5 online) .
To determine which HLA alleles were significantly associated with vitiligo in the absence of DRB1*07:01, we deleted all the samples with DRB1*07:01 from both the case and control groups and then analyzed the data. B*37:01 and DRB1*10:01 were significantly increased, whereas B*08:01 and DRB1*03:01 (Table 3) were significantly reduced in vitiligo cases in both initial and replication studies. In A*33:01-negative cases, B*37:01, B*44:03, DRB1*07:01, and DRB1*10:01 were significantly increased and DRB1*03:01 was significantly reduced as compared with A*33:01-negative controls in both initial and replication studies ( Supplementary Table S6 online). In B*44:03-negative cases too, we observed a significant increase of B*37:01, DRB1*07:01, and DRB1*10:01 and a significant decrease of DRB1*03:01 as compared with B*44:03-negative controls in both the populations studied ( Supplementary Table S7 online). DRB1*07:01 remained significantly increased in B*37:01-negative patient samples also from North India (Po5.69 Â 10 À33 , odds ratio (OR) ¼ 3.03, 95% confidence interval (CI) ¼ 2.51-3.66) and Gujarat (Po1.33 Â 10 À17 , OR ¼ 3.87, 95% CI ¼ 2.78-5.39, data not shown).
HLA-C alleles were studied only in North Indian vitiligo cases (N ¼ 404) and healthy controls (N ¼ 438). We did not see any significant increase in HLA-C group 1 and group 2 alleles (based on Ser 77 /Asn 80 and Asn 77 /Lys 80 , respectively) in vitiligo as compared with controls ( Supplementary Table S1 online). In the absence of C*07:01, which was significantly increased in vitiligo cases, DRB1*07:01 still remained significantly increased (30% in vitiligo vs. 23.08% in controls) in cases as compared with controls (Po0.047, OR ¼ 1.42, 95% CI ¼ 0.99-2.06). However, in DRB1*07:01negative samples, C*07:01 does not remain significant (14.09% in vitiligo vs. 8.81% in controls) in vitiligo cases when compared with controls (Po0.053, OR ¼ 1.69, 95% CI ¼ 0.95-3.03), suggesting that association of C*07:01 is probably because of it being in LD with DRB1*07:01.
Estimation of HLA haplotype frequencies was done using the expectation maximization algorithm (Excoffier and Slatkin, 1995; Excoffier et al., 2005) with Arlequin Ver 3.5 (Table 4 ). Analysis of two-locus haplotypes revealed that (Table 5 ) haplotypes A*33:01-DRB1*07:01 and B*44:03-DRB1*07:01 were significantly increased, and A*26:01-DRB1*03:01 was significantly reduced in vitiligo cases, in both initial and replication studies. Four-locus haplotypes were constructed for North Indian samples and a significant increase of A*33:01-C*07:01-B*44:03-DRB1*07:01 and A*02:01-C*07:01-B*44:03-DRB1* 07:01, and a significant reduction in haplotype A*26:01-C* 07:02-B*08:01-DRB1*03:01 in vitiligo patients was observed as compared with controls ( Supplementary Table S8 online).
HLA class I and II alleles and haplotypes in different manifestations of vitiligo: generalized and localized vitiligo as compared with unaffected controls
To study the association of MHC alleles with different manifestations of vitiligo, cases were divided into two clinical types-generalized and localized. A*33:01, B*44:03, C*07:01, and DRB1*07:01 were significantly increased in the initial study in both generalized and localized vitiligo. However, only B*44:03 and DRB1*07:01 were associated in the replication study with both the generalized and localized types of vitiligo (Table 2 and Supplementary Table S1 online).
Alleles associated with different manifestations of vitiligo were HLA-A*02:01, B*37:01, B*57:01, DRB1*04:03, and DRB1*10:01, which were significantly increased, and A*31:01, B*58:01, C*04:01, DRB1*01:01, DRB1*11:01, and DRB1*15:02 were significantly reduced in generalized vitiligo cases and not in localized vitiligo cases from North India. HLA-A*30:01, A*33:01, and A*68:01 were significantly increased, and B*58:01 and DRB1*01:01 were significantly reduced in generalized vitiligo cases and not in localized vitiligo cases from Gujarat as compared with unaffected controls.
In the absence of DRB1*07:01, B*37:01 was significantly increased in both North Indian and Gujarati patients, irrespective of the type of vitiligo. In addition, A*68:01 and DRB1*10:01 were significantly increased in patients from Gujarat and B*13:01, B*15:02, DRB1*12:02, and DRB1*14:04 were significantly increased in North Indian patients, irrespective of the type of vitiligo. A*33:01 and B*44:03 were increased in localized cases and DRB1*10:01 was increased in generalized cases from North India (Table 3) .
Haplotype A*33:01-B*44:03-DRB1*07:01 (Table 4 ) was significantly increased in both generalized and localized cases in the initial study and only in generalized cases in the replication study. A*24:02-B*44:03-DRB1*07:01 was significantly increased in generalized cases from North India, whereas both generalized and localized cases from Gujarat showed a significant increase in the frequency of this haplotype when compared with unaffected controls. Haplotype A*02:01-B*44:03-DRB1*07:01 was significantly increased in both generalized and localized vitiligo cases from North India.
Two-locus haplotype analysis showed that B*44:03-DRB1*07:01 was significantly increased in both generalized and localized cases in both initial and replication studies (Table 5) . A*33:01-DRB1*07:01 and A*02:01-DRB1*07:01 were significantly increased in both generalized and localized vitiligo cases in the initial study; however, only haplotype A*33:01-DRB1*07:01 was significantly increased in generalized vitiligo cases from Gujarat. Haplotype A*26:01-DRB1*03:01 was significantly reduced in both generalized and localized cases from North India and Gujarat, although P-value did not reach statistical significance for localized cases from Gujarat because of smaller sample size. B*08:01-DRB1*03:01 was significantly reduced in both generalized and localized vitiligo cases from North India and Gujarat.
Specific amino-acid signatures of HLA peptide-binding pockets predispose to vitiligo
Amino-acid signatures of the peptide-binding pockets of HLA-A, -B, and -DRB1 were compared in vitiligo cases with unaffected controls (Figure 1 and Supplementary Tables S9 and S10 online). For HLA-A and -B, five key residues constituting the B pocket (positions 9, 45, 63, 66, and 67) and four key residues constituting the F pocket (positions 77, 80, 81, and 116) of the a1 and a2 domains of the a-chain were investigated (Sidney et al., 2008) . For DRB1, 11 residues representing integral parts of peptide-binding pockets of DR b-chain were analyzed at positions 26, 28, 30, 37, 47, 67, 70, 71, 74, 77, and 86 (Menconi et al., 2010) . The protein sequences were downloaded from the HLA database (http:// www.ebi.ac.uk/imgt/hla/align.html), and the amino acids present at the aforesaid positions were compared in patients and controls. Approximately 8-10% of the samples were homozygous for one or more loci in patients and controls. Thus, to avoid overrepresentation of certain amino acids at particular positions because of homozygosity, we considered phenotype frequencies of the alleles; i.e., the homozygous samples were counted as having only one allele. The results show that that Glu 28b , Leu 30b /Arg 30b Phe 37b , Tyr 47b , Ile 67b , Asp 70b , Arg 71b , Gln 74b , Thr 77b , and Gly 86b make the molecular signature of the peptide-binding pockets of DRB1 for predisposition to develop vitiligo in both the initial and replication studies (Figure 1 ). Asp 28b , Tyr 30b /Cys 30b , Ser 37b , Phe 47b , Leu 67b , Gln 70b , Lys 71b , Ala/Arg 74b , Asn 77b , and Val 86b OR was calculated by using Woolf's method with Haldane's modification. All patient and control samples with DRB1*07:01 allele were removed to study the contribution of alleles independent of DRB1*07:01 in susceptibility to vitiligo. All vitiligo (N=680), generalized (N=496), and localized (N=184) vitiligo samples from North India were compared with healthy controls (N=654) for HLA-A, HLA-B, and HLA-DRB1 loci. From Gujarat, all vitiligo (N=170), generalized (N=117), and localized (N=53) vitiligo samples were compared with 314 unaffected controls for HLA-A locus. Overall, 170 vitiligo samples, 116 generalized and 54 localized, were compared with 314 samples from unaffected controls for HLA-B locus, and 171 vitiligo samples, 117 generalized and 54 localized, were compared with 330 unaffected controls for HLA-DRB1 locus. make the molecular signature of DRB1 for the protection from vitiligo in both North India and Gujarat. The molecular signature for HLA-A alleles for predisposition to develop the disease is actually specific for HLA-A allele A*33:01, which is in LD with DRB1*07:01. For HLA-B locus, Lys 45a , Glu 63a , Ser 67a , Asn 77a , Thr 80a , Ala 81a , and Ser 99a makes the molecular signature for predisposition to develop vitiligo, and Thr 45a , Asn 63a , Phe 67a , Ser 77a , Asn 80a , Leu 81a , and Tyr 99a makes the molecular signature for protection from vitiligo in both the initial and replication studes. In addition, significant increase of Met 45a , Cys 67a , Asp 77a , and Asp 116a in North Indian samples suggests the involvement of alleles other than the predisposing alleles, which may be in low frequencies (Figure 1, Supplementary Table S10 online). Subtle differences were observed in the molecular signatures of the peptide-binding pockets of DR b-chain in localized and generalized vitiligo. Interestingly, localized vitiligo patients show similarities in the amino-acid signatures with generalized vitiligo at positions Glu 28b , Leu 30b , Phe 37b , Tyr 47b , and Gln 74b in both the initial and replication studies. However, they show similarities with unaffected controls at positions Arg 30b /Cys 30b , Ser 37b , Ile 67b /Leu 67b Asp 70b , and OR was calculated by using Woolf's method with Haldane's modification. Two-locus haplotypes (HLA-A-HLA-DRB1 and HLA-B-HLA-DRB1) were deduced from three-locus haplotypes (Arlequin ver 3.5) for patients and controls as described in Table 4 .
Ala 74b in North Indians, and Cys 30b , Ser 37b , Asp 70b , Arg 71b / Lys Ser 71b , Ala 74b /Arg 74b , and Thr 77b /Asn 77b in Gujaratis (data not shown).
DISCUSSION
Our results show that A*33:01, B*44:03, and DRB1*07:01 were significantly increased in both initial and replication studies, suggesting that these alleles are the markers for vitiligo in both North India and Gujarat. Association of DRB1*07:01 with vitiligo seems to be primary, because in the absence of A*33:01, B*44:03, or B*37:01, DRB1*07:01 still remains highly significant in both the populations studied, whereas the converse was not true. The basic predisposing alleles in both localized and generalized vitiligo are the same; however, similarities with the controls in terms of allele frequencies of some alleles and amino-acid signature of the DR b-chain seem to be protective from generalized distribution of the lesions in localized vitiligo ( Supplementary  Table S11 online).
Haplotype analysis showed the presence of 177 and 68 DRB1*07:01 haplotypes in North Indian and Gujarati cases, respectively, suggesting that enough recombinational events have taken place during the course of evolution, giving rise to such a diversity of haplotypes; however, some of the predisposing and protective haplotypes are still conserved. The haplotype A*33:01-B*44:03-DRB1*07:01 was significantly increased in generalized and localized vitiligo cases from North India and only generalized cases from Gujarat. Although the localized cases from Gujarat showed an OR of 2.25 for this haplotype, the P-value was not significant, probably because of smaller sample size for the localized cases from Gujarat.
Very few studies have been conducted on association of HLA alleles with vitiligo using low-resolution molecular methods and still fewer using high-resolution typing methods. A study on 41 Turkish vitiligo cases showed DRB1*03, DRB1*04, and DRB1*07 to be increased in the vitiligo cases (Tastan et al., 2004) . However, we observed DRB1*07:01 to be positively associated and DRB1*03:01 to be negatively associated with vitiligo in both initial and replication studies. Presence of DRB1*07:01 has been reported in patients from Slovakia (Buc et al., 1998) and China (Ren et al., 2009) , whereas HLA class I alleles have not been reported in these studies. A meta-analysis of 11 case-control studies (N ¼ 777) showed that class I allele HLA-A2 is associated with vitiligo (Liu et al., 2007) . HLA-A2 is a cluster of 266 alleles, one of which, HLA-A*02:01, was significantly increased in generalized vitiligo cases (Po0.001, OR ¼ 1.57) from North India, although only 14.59% of the generalized vitiligo patients and 9.76% of unaffected controls had this allele ( Table 2) . The haplotype A*02:01-B*44:03-DRB1*07:01 was significantly increased in both generalized (2.64%) and localized cases (1.3%) from North India as compared with controls who lacked this haplotype altogether. However, our data suggest that the primary association of HLA with vitiligo in North India and Gujarat is not with A*02:01, but with A*33:01, B*44:03, and DRB1*07:01.
Analysis of two-locus haplotypes for HLA-A-DRB1 and HLA-B-DRB1 suggests that the haplotype B*44:03-DRB1*07:01 is the marker for both generalized and localized vitiligo in both the populations studied. DRB1*07:01 was also in LD with A*02:01, A*33:01, and B*57:01. These data suggest that the autoreactive CD4 þ T-helper cells are restricted by HLA-DRB1*07:01 and the autoreactive CD8 þ cytotoxic T cells may be restricted by HLA-A*33:01, A*02:01, B*44:03, and B*57:01 in the Indian populations studied.
Association of MHC alleles with a disease gains importance because of the antigen-presenting function of the MHC. The peptides presented by the MHC molecules have allelespecific motifs (Falk et al., 1991) . The affinity of the peptide to a particular MHC molecule is determined by the amino-acid residues present in peptide-binding pockets of the peptidebinding groove. Shared amino acids in the peptide-binding pockets have been demonstrated in autoimmune diseases such as Type 1 diabetes (Todd et al., 1987) , rheumatoid arthritis (Winchester, 1994) , and thyroiditis (Menconi et al., 2010) . Investigation of amino-acid signatures for the peptidebinding pockets of HLA-A and HLA-B a-chain and HLA-DR b-chain revealed specific molecular signatures for predisposition and protection from the disease. These results suggest affinity of autoantigenic peptides for predisposing MHC class II and class I molecules that may be involved in orchestrating (through CD4 þ T cells) and implementing the autoimmune responses (through CD8 þ T cells) in vitiligo, respectively.
Generalized vitiligo is considered to be an autoimmune disease, whereas localized vitiligo has not been considered an autoimmune disease. We observed B*44:03 and DRB1*07:01 to be predisposing in both generalized and localized vitiligo patients in both the populations studied, beside some differences in the frequencies of some other alleles. To our knowledge, this is previously unreported. Association of MHC alleles with localized vitiligo clearly shows that there is a need to relook at the etiopathogenesis of localized vitiligo. Although it may be an autoimmune disorder, similarities with unaffected controls in terms of HLA alleles and amino-acid signatures of the peptide-binding pockets of DR b-chain may be contributing to the localized distribution of the lesions.
MATERIALS AND METHODS
Patient group
DNAs were extracted from 1,404 North Indian patients with vitiligo enrolled at Dr Ram Manohar Lohia Hospital and All India Institute of Medical Sciences, New Delhi, after obtaining informed consent. These subjects belonged to North Indian states of Uttar Pradesh, Himachal Pradesh, Bihar, Haryana, Punjab, and Delhi. All cases and control samples were collected after Institutional Human Ethics Committee's clearance from all the institutes/hospitals involved, following the Declaration of Helsinki Principles. Diagnosis of vitiligo was based on clinical examination done by dermatologists. Clinically, the cases were classified as having generalized (vulgaris, acrofacial, and universalis) or localized (focal, acral, mucosal, and segmental) forms of vitiligo. The replication study was carried out on 355 vitiligo cases from Gujarat, a state in west of India (Table 1) .
It may be pertinent to mention here that the two groups studied in the initial and replication studies form two independent endogamous groups that do not inter-marry.
Unaffected controls
A total of 902 ethnically matched unaffected controls from North India were used in the initial study and 441 ethnically matched unaffected controls from Gujarat were studied in the replication study. None of the unaffected controls had personal or family history of vitiligo or any other autoimmune disease. Of the 902 controls from North India, blood samples of 308 were collected at National Institute of Immunology, Dr Ram Manohar Lohia Hospital and All India Institute of Medical Sciences, New Delhi, and the remaining 594 samples were procured from the Institute of Genomics and Integrative Biology, New Delhi, which were collected from the aforesaid states of North India as a part of the Indian Genome Variation program, and the details of the sample collection have been explained elsewhere (Consortium, 2005) .
Study of HLA-A, HLA-B, HLA-C, and HLA-DRB1 alleles DNA extraction was carried out by standard procedures from blood samples collected in anticoagulant EDTA. Alleles of HLA-A, HLA-B, HLA-C, and HLA-DRB1 were studied using PCR, followed by hybridization with sequence-specific oligonucleotide probes as described earlier (Israni et al., 2009 ), using a bead-based technology (Luminex, Austin, TX) following the manufacturer's instructions (Labtype SSO kit from One Lambda, Canoga Park, LA). All North Indian samples were typed for HLA-A, HLA-B, and HLA-DRB1 loci. A total of 404 vitiligo and 438 unaffected control samples from North India were typed for HLA-C locus. Of the 355 Gujarat cases, 354, 353, and 355 cases were typed for HLA-A, HLA-B, and HLA-DRB1 loci, respectively, and of the 441 unaffected controls from Gujarat population, 408, 407, and 441 individuals were typed for three loci, respectively. Differences in the sample numbers studied for different loci are because of amplification failures in some samples. The latest nomenclature for the HLA system was used to designate the alleles of the three loci studied (Marsh et al., 2010) .
Haplotype analysis
Estimation of HLA haplotype frequencies was carried out using the expectation maximization algorithm (Excoffier and Slatkin, 1995; Excoffier et al., 2005) . Arlequin Ver 3.5 (Excoffier et al., 2005) was run using the following settings: expectation maximization algorithm performed at the haplotype level, e ¼ 1eÀ7, five significant digits for output, 50 starting points for expectation maximization algorithm, and a maximum of 1,000 iterations (Bettencourt et al., 2008) at http://cmpg.unibe.ch/software/arlequin35/. Three-and four-locus haplotypes were thus constructed for both patient and controls samples to identify predisposing and protective haplotypes in the two populations. Two-locus haplotypes were derived from three-locus haplotypes.
Statistical analysis
Vitiligo samples were compared with their respective unaffected controls using w 2 -analysis using Stata 9.2 statistical program. Fisher's exact test was used when the numbers were five or less in any group; i.e., in cases or controls for any allele. In such cases, ORs were calculated using Woolf's method (Woolf, 1955) with Haldane (1956) modification as described earlier (Rani et al., 1998) .
